Objective. Gouty arthritis (GA) is a noninfectious inflammatory disease characterized by self‐limited and severe pain. Huzhang Tongfeng granule is one of the most effective traditional Chinese medicines in the treatment of acute GA. However, its effects on the inflammatory factors in the process of acute gout inflammation remain unknown. In the present study, we aimed to evaluate the effect of Huzhang Tongfeng granule on the expressions of Cyr61 and related inflammatory factors in both experimental gout models in vivo and in vitro. Methods. Huzhang Tongfeng granule was provided by the pharmaceutical preparation room of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. The expressions of Cyr61, IL‐1β, TNF‐α, and IL‐6 in monosodium urate‐ (MSU‐) induced rat models and fibroblast‐like synoviocytes (FLSs) were determined by RT‐PCR, Western blotting analysis, ELISA, immunohistochemistry, and hematoxylin and eosin staining. Results. Huzhang Tongfeng granule could downregulate the expressions of IL‐1β, TNF‐α, and IL‐6 to some extent by inhibiting the expression of Cyr61. Conclusions. Collectively, our findings indicated that Cyr61 was highly expressed in rat models of gout. By inhibiting the expression of Cyr61, Huzhang Tongfeng granule could partially attenuate the inflammation induced by MSU crystal.

Introduction: A number of studies have reported a high correlation between psoriasis and metabolic syndrome (MetS), and tobacco smoking is one independent risk factor accounting for the increased prevalence both for psoriasis and MetS. However, few studies have been conducted to assess the...

Background: Acute gouty arthritis (GA) is the main clinical manifestation and the most common initial symptom of gout. The treatment of acute GA involves the use of colchicine, non-steroidal anti-inflammatory drugs, and corticosteroids. Because of the side effects of these drugs, their clinical applications are limited. The use of traditional Chinese medicine for the treatment of acute GA has unique advantages. The aim of this trial is to clarify the treatment efficacy, safety, and recurrence control efficacy ofHuzhanggranules (HZG) in patients with GA showing dampness-heat syndrome.Methods/design: This double-blind, randomized, controlled trial was planned to be conducted between July 1, 2020, and December 31, 2022. A sample size of 267 participants (89 per group) with GA will be randomly assigned to three treatment groups in the ratio of 1:1:1: HZG, etoricoxib, and placebo groups. The study duration is 13 days, including a 1-day screening period, 5-day intervention period, and 1-week follow-up period. The primary outcome is analgesic effectiveness, assessed as pain in the worst-affected joint, which will be measured using the visual analog scale. Secondary outcomes include the patient’s assessment of pain in the primary study joint, patient’s global assessment of response to therapy, investigator’s global assessment of response to therapy, investigator’s assessment of tenderness and swelling of the study joint, and TCM syndromes. Furthermore, the number, nature, and severity of adverse events will be recorded.Discussion: This study will provide evidence regarding the clinical efficacy and safety of Chinese medicine treatment for acute gouty arthritis. This study will provide noteworthy findings.Trial registration: ClinicalTrials.govNCT04462666. Registered on July 05, 2020 (first version).

The thin-film transistors (TFTs) based on amorphous-InSnZnO (a-ITZO) as the active layer are prepared by RF magnetron sputtering at room temperature. The conditions for the preparation of a-ITZO TFT are optimized in terms of sputtering gas ambiance, active layer thickness, annealing ambiance, annealing temperature and annealing time. A decent a-ITZO TFT with a field-effect mobility of 9.03 cm ² /Vs, a subthreshold swing of 230 mV/dec and an on/off ratio of 5.72 ×10 ⁷ is obtained at a low annealing temperature of 150 ℃. The test results provide the experimental basis for low-temperature annealing of a-ITZO TFTs for future flexible applications.